Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 773-778

  Xu, Hairong ^a   Niu, Xiaohui ^a   Zhang, Qing ^a   Hao, Lin ^a   Ding, Yi ^a   Liu, Weifeng ^a   Yao, Lu ^b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antiangiogenic therapy; Combination therapy; Osteosarcoma; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ENDOSTAR; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MICROVASCULATURE; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; OSTEOSARCOMA; TUMOR CELL LINE;

EID: 79960314799     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.334     Document Type: Article

References (35)

1. Bielack SS, Carrle D, Hardes J, Schuck A and Paulussen M: Bone tumors in adolescents and young adults. Curr Treat Options Oncol 9: 67-80, 2008.
2. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606, 1986.
3. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M and Picci P: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 41: 2836-2845, 2005.
4. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-327, 2008.
5. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C and Huvos AG: Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163-2177, 1979.
6. Norman Jaffe: Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30: 1627-1631, 1972.
7. Niu XH, Cai YB, Zhang Q, Hao L and Ding Y: Long-term results of combined therapy for primary osteosarcoma in extremities of 189 cases. Zhonghua Wai Ke Za Zhi 43: 1576-1579, 2005.
8. Carrle D and Bielack SS: Current strategies of chemotherapy in osteosarcoma. Int Orthop 30: 445-451, 2006.
9. Daw NC, Billups CA, Rodriguez-Galindo C, et al: Metastatic osteosarcoma. Cancer 106: 403-412, 2006.
10. Ruegg C and Mutter N: Anti-angiogenic therapies in cancer: achievements and open questions. Bull Cancer 94: 753-762, 2007.
11. O'Reilly MS, Holmgren L, Chen C and Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692, 1996.
12. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 312: 594-607, 2006.
13. Balasubramanian L and Evens AM: Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 18: 354-359, 2006.
14. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
15. Los M and Voest EE: The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 28: 93-105, 2001.
16. Bozec A, Lassalle S, Gugenheim J, et al: Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 95: 722-728, 2006.
17. Kato T, Sato K, Kakinuma H and Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54: 5143-5147, 1994.
18. te Velde EA, Vogten JM, Gebbink MF, van Gorp JM, Voest EE and Borel Rinkes IH: Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 89: 1302-1309, 2002.
19. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180, 1995.
20. Hockel M, Schlenger K, Hockel S and Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59: 4525-4528, 1999.
21. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP and Ramakrishnan S: Synergy between angiostatin and endostatin: inhi-bition of ovarian cancer growth. Cancer Res 60: 2190-2196, 2000.
22. Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047, 2000.
23. Lewis IJ, Nooij MA, Whelan J, et al: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99: 112-128, 2007.
24. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK and Rodriguez GC: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5: 587-591, 1999.
25. Kreuter M, Bieker R, Bielack SS, et al: Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res 10: 8531-8537, 2004.
26. Mikulic D, Ilic I, Cepulic M, et al: Tumor angiogenesis and out-come in osteosarcoma. Pediatr Hematol Oncol 21: 611-619, 2004.
27. Kaya M, Wada T, Akatsuka T, et al: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577, 2000.
28. Tsunemi T, Nagoya S, Kaya M, et al: Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res 159-166, 2003.
29. Kaya M, Wada T, Nagoya S and Yamashita T: Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci 12: 562-567, 2007.
30. Dutour A, Monteil J, Paraf F, et al: Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 11: 311-319, 2005.
31. Eilber FR and Rosen G: Adjuvant chemotherapy for osteosarcoma. Semin Oncol 16: 312-322, 1989.
32. Wildiers H, Guetens G, De Boeck G, et al: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88: 1979-1986, 2003.
33. Hagendoorn J, Tong R, Fukumura D, et al: Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 66: 3360-3364, 2006.
34. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989, 2001.
35. Xu HR, Tian W, Niu XH, et al: In vitro study of recombinant human endostatin in combination with adriamycin on human osteosarcoma cell OS-732. Chin J Bone Tumor Bone Dis 7: 129-132, 2008.